BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide whose sequence reproduces a fragment of a protective human gastric juice protein. Preclinical research uses it as a stable model compound for studying cytoprotection and connective-tissue regeneration. This page collects the chemistry of the molecule and the main directions of its study. It is reference material about a research reagent, not medical advice.

Chemistry and structure

The molecule is built from 15 amino-acid residues: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular formula C62H98N16O22, molar mass about 1419.5 g/mol, CAS (Chemical Abstracts Service number) number 137525-51-0. A high proline content gives the chain rigidity and raises its resistance to proteolysis, so the peptide stays stable in the acidic gastric environment [1].

Mechanism of action

Mechanistically BPC-157 is described as a cytoprotective and pro-angiogenic compound rather than a drug with one established receptor: no single high-affinity receptor has been identified for it so far. Its pro-angiogenic activity has been linked to activation and up-regulation of VEGFR2 with downstream signalling through the Akt/eNOS axis [9]. In tendon-fibroblast culture, the peptide enhanced cell outgrowth from explants, supported their survival under oxidative stress, and accelerated migration with reorganisation of the actin cytoskeleton [10]. A separate line of work showed increased growth-hormone-receptor expression in the same cells: a plausible route by which the compound could raise a tissue's sensitivity to an already-present growth signal rather than supply its own [12].

Directions of preclinical research

Historically the molecule was described by researchers at the University of Zagreb in the context of gastrointestinal mucosal protection [1][6]. Later work broadened the range of models and tissues in which the peptide was studied.

Connective tissue: tendon and ligament

This is one of the most closely studied directions for BPC-157 outside the gastrointestinal tract. In a rat Achilles-detachment model, BPC-157 was reported to promote healing at the tendon-to-bone junction and to oppose the aggravating effect of a corticosteroid [11]. Effects in transected-Achilles work were attributed to tendon-fibroblast outgrowth, survival under oxidative stress and accelerated migration [10], and a separate study of the same cells showed increased growth-hormone-receptor expression [12]. A review of musculoskeletal healing systematises this and related data on the peptide's effect on tendons, ligaments and muscle in animal models [3].

Angiogenesis and wound healing

An alkali-burn skin model reports faster healing together with stimulation of proliferation, cell migration and vessel formation in vitro [2]. These observations line up with the VEGFR2 mechanism described above [9], and form the main case for the peptide's pro-angiogenic action outside the gastrointestinal tract.

Gastrointestinal cytoprotection

This is BPC-157's home turf: the compound was isolated from gastric juice and characterised across models of gastrointestinal lesions, where stability in the acidic environment is central to its pharmacological story [1][6]. An alcohol-induced gastric mucosal injury model extends this profile toward a more systemic inflammatory syndrome and shows the compound's protective effect beyond local damage [5].

Brain-gut axis (CNS)

A review considers systemic effects of the peptide beyond the digestive tract, including a possible link between gut and central processes [4]. A separate rat study examined BPC-157 in a hippocampal ischemia/reperfusion injury model [7]; this direction has relatively fewer studies compared with the gastrointestinal and tendon models.

Human data and reagent status

No published controlled study of BPC-157 in humans exists: the compound has not gone through the clinical-trial phases required of medicines. A 2025 literature and patent review states this gap plainly: despite a large volume of preclinical publications, the compound's path to an approved medical use has not been completed in any jurisdiction [8]. There is no approved protocol for use in humans, and no regulator has approved BPC-157 as a medicine. Any use therefore remains research only.

Limits of the evidence base

  • The evidence is mostly preclinical. Nearly every result cited here comes from cell cultures, rats or mice, often with small experimental group sizes.
  • Human data is absent. BPC-157's pharmacokinetics, dose-response relationship and long-term safety in humans have not been studied in published controlled research.
  • Authorship concentration. A large share of the BPC-157 corpus originates from a single research group in Zagreb [8]; independent replications by other laboratories are few.
  • No approved indication. No regulator anywhere has approved BPC-157 as a medicine; the compound remains a laboratory reagent.

Dosing context

This monograph deliberately contains no dosing schedules. Research protocols vary by route of administration, animal species and injury model, and none of the studies cited establishes a human regimen. The reconstitution-and-handling laboratory context is kept in a separate reference: see the BPC-157 dilution guide and the general peptide dosage chart.

Laboratory handling, stability and purity

BPC-157 is supplied as a lyophilised powder and, in research settings, behaves like other short peptides: stored cold and dry, protected from light, until reconstitution. Reconstitution is done with a suitable solvent immediately before a series of experiments; once in solution the peptide is sensitive to light, heat and repeated freeze-thaw cycles, so the working solution is generally split into aliquots and repeated freezing is avoided. The high proline content of the sequence, described above, raises the peptide's resistance to enzymatic breakdown and partly explains why it stays workable even after reconstitution under proper storage [1]. Purity and identity of a specific batch should be established from a certificate of analysis (COA), not from general literature data.

BPC-157 alone versus in combination with TB-500

Unlike thymosin β4 / TB-500, a peptide with a different mechanism of action (actin sequestration and cell migration rather than cytoprotection and angiogenesis), BPC-157 is described more as tuning the environment for repair: blood supply, cell survival and receptor sensitivity to signals already present. A detailed breakdown of both mechanisms, the research models behind them, and an honest section on the limits of the evidence for the combination is covered in the separate BPC-157 + TB-500 monograph.

Quality control at Longeva

Longeva sends samples itself to independent third-party labs. Batches ship with a COA (certificate of analysis) that we publish in an open archive. For a specific lot the certificate becomes available once independent testing is complete.

See also

Buy the reagent: BPC-157. Reconstitution and literature dose ranges: BPC-157 dilution guide. The peptide is also available combined with TB-500: BPC-157 and TB-500, and standalone TB-500 on the TB-500 page.

Research material. Not a medicinal product.